20 September 2014 2015 Prohibited List Summary of Major Modifications and Explanatory Notes SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF- COMPETITION) PROHIBITED SUBSTANCES S1: Anabolic Agents Changes were made to reflect current scientific nomenclature. 5β-androstane-3α,17β-diol was added to the examples of testosterone metabolites. S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics The title of this section has been changed: Mimetics have been added to the title to reflect the fact that synthetic analogs are also prohibited under this section. Please note that all the substances named as examples in this revised section of the 2015 Prohibited List where already considered prohibited under previous Prohibited Lists, as applicable. The ESA sub-section has been expanded by adding the non-erythropoietic EPO-Receptor agonists. In addition, the HIF stabilizer sub-section has been placed in a separate paragraph to highlight the growing importance of these drugs and to specifically identify HIF activators such as xenon and argon. Note that cyanocobalamin (vitamin B12) is not prohibited. Examples of Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) releasing factors have now been identified. A Corticotrophin releasing factor has now been added as an example. GH releasing factors have been divided in a more precise categorization and several examples of each have been added to illustrate their different pharmacological properties. IGF-1 has been moved to the other growth factor section. Note that Platelet Derived Plasma preparations are not prohibited. S4. Hormone and Metabolic Modulators Trimetazidine was originally included in S6.b based upon the similarity of its chemical structure to some of the listed Stimulants. It has been moved to the newly created sub-section S4.5.c as it is pharmacologically classified as a modulator of cardiac metabolism. AMPK activators were re-described to reflect current nomenclature. S5. Diuretics and Masking Agents The title and subsequent paragraphs has been modified by the removal of the word “other” to reflect that diuretics are not only masking agents but can also be abused for other purposes such as notably the induction of rapid weight loss. The last paragraph has been reworded for the sake of clarity. The principle and processes identified in the previous version of the Prohibited List remain unchanged. PROHIBITED METHODS M2. Chemical and Physical Manipulation The term “surgical procedures” has been added to the sentence describing the situations in which the administration of intravenous infusions or injections of more than 50 mL per 6 hours are permitted when medically required. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants: For the sake of clarification, topical/ophthalmic imidazole derivatives have been mentioned as exceptions of non-prohibited stimulants. Phenmetrazine has been moved from section S6.a to S6.b to reflect the fact that it is metabolized into fenbutrazate, which is already listed under S6.b. The List now clearly identifies the whole family of phenethylamine derivatives as being prohibited to address the growing number of illegal, designer stimulants derived from phenethylamine. Trimetazidine has been transferred to the newly created section S4.5.c (see above). S9: Glucocorticoids: Glucocorticosteroids are described as Glucocorticoids to reflect current nomenclature and use. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1: Alcohol: Following the request of World Karate Federation (WKF), karate was removed from the list of sports in which alcohol is prohibited P2. Beta-blockers The World Underwater Federation (CMAS) has, at its request, been added to the group of International Federations prohibiting the use of Beta-blockers in competition for certain disciplines. MONITORING PROGRAM Following sufficient collection of data leading to clear conclusions, monitoring of pseudoephedrine below 150 microgram per milliliter will cease in 2015. Telmisartan, an atypical angiotensin II receptor antagonist with apparent partial PPARδ receptor agonist properties (prohibited under S4.5.b), was added to the Monitoring Program to assess the abuse of this substance. Meldonium, a drug with potential cardiac effects, was added to the Monitoring Program to assess the abuse of this substance.

20 September 2014 2015 Prohibited List Summary of Major Modifications and Explanatory Notes SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF- COMPETITION) PROHIBITED SUBSTANCES S1: Anabolic Agents Changes were made to reflect current scientific nomenclature. 5β-androstane-3α,17β-diol was added to the examples of testosterone metabolites. S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics The title of this section has been changed: Mimetics have been added to the title to reflect the fact that synthetic analogs are also prohibited under this section. Please note that all the substances named as examples in this revised section of the 2015 Prohibited List where already considered prohibited under previous Prohibited Lists, as applicable. The ESA sub-section has been expanded by adding the non-erythropoietic EPO-Receptor agonists. In addition, the HIF stabilizer sub-section has been placed in a separate paragraph to highlight the growing importance of these drugs and to specifically identify HIF activators such as xenon and argon. Note that cyanocobalamin (vitamin B12) is not prohibited. Examples of Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) releasing factors have now been identified. A Corticotrophin releasing factor has now been added as an example. GH releasing factors have been divided in a more precise categorization and several examples of each have been added to illustrate their different pharmacological properties. IGF-1 has been moved to the other growth factor section. Note that Platelet Derived Plasma preparations are not prohibited. S4. Hormone and Metabolic Modulators Trimetazidine was originally included in S6.b based upon the similarity of its chemical structure to some of the listed Stimulants. It has been moved to the newly created sub-section S4.5.c as it is pharmacologically classified as a modulator of cardiac metabolism. AMPK activators were re-described to reflect current nomenclature. S5. Diuretics and Masking Agents The title and subsequent paragraphs has been modified by the removal of the word “other” to reflect that diuretics are not only masking agents but can also be abused for other purposes such as notably the induction of rapid weight loss. The last paragraph has been reworded for the sake of clarity. The principle and processes identified in the previous version of the Prohibited List remain unchanged. PROHIBITED METHODS M2. Chemical and Physical Manipulation The term “surgical procedures” has been added to the sentence describing the situations in which the administration of intravenous infusions or injections of more than 50 mL per 6 hours are permitted when medically required. SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants: For the sake of clarification, topical/ophthalmic imidazole derivatives have been mentioned as exceptions of non-prohibited stimulants. Phenmetrazine has been moved from section S6.a to S6.b to reflect the fact that it is metabolized into fenbutrazate, which is already listed under S6.b. The List now clearly identifies the whole family of phenethylamine derivatives as being prohibited to address the growing number of illegal, designer stimulants derived from phenethylamine. Trimetazidine has been transferred to the newly created section S4.5.c (see above). S9: Glucocorticoids: Glucocorticosteroids are described as Glucocorticoids to reflect current nomenclature and use. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1: Alcohol: Following the request of World Karate Federation (WKF), karate was removed from the list of sports in which alcohol is prohibited P2. Beta-blockers The World Underwater Federation (CMAS) has, at its request, been added to the group of International Federations prohibiting the use of Beta-blockers in competition for certain disciplines. MONITORING PROGRAM Following sufficient collection of data leading to clear conclusions, monitoring of pseudoephedrine below 150 microgram per milliliter will cease in 2015. Telmisartan, an atypical angiotensin II receptor antagonist with apparent partial PPARδ receptor agonist properties (prohibited under S4.5.b), was added to the Monitoring Program to assess the abuse of this substance. Meldonium, a drug with potential cardiac effects, was added to the Monitoring Program to assess the abuse of this substance.

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2018 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2018 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); Bolandiol (estr-4-ene-3β,17β-diol); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; S0 S1 Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine, LGD-4033, ostarine and RAD140), tibolone, zeranol and zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Argon; Cobalt; Molidustat; Roxadustat (FG-4592); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) inhibitors, e.g. Luspatercept; Sotatercept. S2 4 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). 2. Peptide Hormones and Hormone Modulators, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin, in males; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin, ipamorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and hexarelin. 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF). Additional growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); S3 S4 5 Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. S5 Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of polymers of nucleic acids or nucleic acid analogues. 2. The use of gene editing agents designed to alter genome sequences and/or the transcriptional or epigenetic regulation of gene expression. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: 1,3-Dimethylbutylamine; 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2018 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2018 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS The following cannabinoids are prohibited: • Natural cannabinoids, e.g. cannabis, hashish and marijuana, • Synthetic cannabinoids e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics. Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Levobunolol; Atenolol; Metipranolol; Betaxolol; Metoprolol; Bisoprolol; Nadolol; Bunolol; Oxprenolol; Carteolol; Pindolol; Carvedilol; Propranolol; Celiprolol; Sotalol; Esmolol; Timolol. P1 www.wada-ama.org

1 Prohibited Substances ANABOLIC AGENTS • Dihydrotestosterone was renamed to its International Non-proprietary Name (INN) (androstanolone). 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one) was added in S1.a as an example of exogenous anabolic steroid. • LGD-4033 and RAD140 were added as further examples of SARMs. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS • For clarity and accuracy Section S2 was reorganized. • ARA290 was removed as an example in this section because current literature suggests it does not meet inclusion criteria. • Deslorelin, goserelin, nafarelin and triptorelin were added as examples of 2.1. • Growth Hormone fragments were included in 2.3 with AOD-9604 and hGH 176-191 added as examples; CJC-1293 was added as example of GHRH and tabimorelin as a further example of GH secretagogue. GHRP-1, -3, -4, and -5 were added as examples of GHRP. • Thymosin- β4 and its derivatives, e. g. TB-500, were added as example of prohibited growth factors. • Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited. S1 S2 BETA-2-AGONISTS • Dosing parameters of salbutamol were revised to make it clear that divided doses of salbutamol may not exceed 800 micrograms over any 12 hours (see figure). Inhaled salbutamol – max. 1600 mcg over 24 hours But not to exceed 800 mcg over any 12 hours 0 12 24 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg • Tulobuterol was added as an example. • The statement on the urinary thresholds was improved. HORMONE AND METABOLIC MODULATORS • Clomifene is now stated by its INN. • In the absence of an INN, the IUPAC name of GW1516, 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl) thiazol-5-yl)methylthio)phenoxy) acetic acid as well as an alternative name (GW501516) were included. • SR9009, a Rev-Erb-α agonist, was added as an example of Activators of the AMP-activated protein kinase (AMPK). S3 Any 12 hour period: max. 800 mcg S4 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2018 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) 2 DIURETICS AND MASKING AGENTS • In consideration of the information published in scientific articles since 2012 that particularly addresses the ability of glycerol to influence the athlete‘s plasma volume and parameters of the Athlete Biological Passport (ABP), the magnitude of glycerol-derived effects is regarded as minimal. Therefore, glycerol has been removed from the Prohibited List. Prohibited Methods CHEMICAL AND PHYSICAL MANIPULATION • M2.2: the permitted volume and timing of intravenous infusions were changed from infusions of no more than 50 mL per 6-hour period to no more than a total of 100 mL per 12-hour period in order to allow greater flexibility for the safe administration of non-prohibited therapeutic substances, for example, iron. • To reflect medical practice, “hospital admissions” has been changed to “hospital treatments” and “clinical investigations” has been clarified as “clinical diagnostic investigations”. GENE DOPING • The definition has been revised to include current and emerging gene manipulating technologies. Substances and Methods Prohibited In-Competition STIMULANTS • 1,3-Dimethylbutylamine was added as an example. This substance can be found in some dietary supplements. S5 M2 M3 S6 CANNABINOIDS • The category Cannabimimetics, e.g. “Spice, JWH-018, JWH-073, HU210” was changed to “synthetic cannabinoids, e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics”. The synthetic cannabinoids are one of the main classes of novel psychoactive substances that have constantly emerging new drugs and changing availability. The previous list of examples continues to be prohibited, but are currently used less commonly. “Other cannabimimetics” replaced these examples. • Cannabidiol is no longer prohibited. Synthetic cannabidiol is not a cannabimimetic; however, cannabidiol extracted from cannabis plants may also contain varying concentrations of THC, which remains a prohibited substance. GLUCOCORTICOIDS • Examples of commonly used glucocorticoids were added for greater clarity. S8 S9 3 Substances Prohibited in Particular Sports ALCOHOL • After careful consideration and extensive consultation, Alcohol was excluded from the Prohibited List. The intent of this change is not to compromise the integrity or safety of any sport where alcohol use is a concern, but rather to endorse a different means of enforcing bans on alcohol use in these sports. The four International Federations (IF) affected by this change have been alerted sufficiently in advance in order to amend their rules and to put in place protocols to test for alcohol use and appropriately sanction athletes who do not abide by the rules of their sport. Control of the process will allow IF more flexibility in applying rules or thresholds as they see fit. The National Anti-Doping Organizations are no longer obliged to conduct tests but may assist IF and National Federations where appropriate. BETA BLOCKERS • For logical consistency, the category known as P2. Beta Blockers was renamed P1. Beta Blockers. MONITORING PROGRAM The following were added to evaluate misuse in sport: • 2-ethylsulfanyl-1H-benzimidazole (bemitil) in- and out-of-competition • Hydrocodone in-competition. Mitragynine and telmisartan were removed from the Monitoring Program because the required information on prevalence was obtained. P1 P2

1 Prohibited Substances ANABOLIC AGENTS • Dihydrotestosterone was renamed to its International Non-proprietary Name (INN) (androstanolone). 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one) was added in S1.a as an example of exogenous anabolic steroid. • LGD-4033 and RAD140 were added as further examples of SARMs. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS • For clarity and accuracy Section S2 was reorganized. • ARA290 was removed as an example in this section because current literature suggests it does not meet inclusion criteria. • Deslorelin, goserelin, nafarelin and triptorelin were added as examples of 2.1. • Growth Hormone fragments were included in 2.3 with AOD-9604 and hGH 176-191 added as examples; CJC-1293 was added as example of GHRH and tabimorelin as a further example of GH secretagogue. GHRP-1, -3, -4, and -5 were added as examples of GHRP. • Thymosin- β4 and its derivatives, e. g. TB-500, were added as example of prohibited growth factors. • Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited. S1 S2 BETA-2-AGONISTS • Dosing parameters of salbutamol were revised to make it clear that divided doses of salbutamol may not exceed 800 micrograms over any 12 hours (see figure). Inhaled salbutamol – max. 1600 mcg over 24 hours But not to exceed 800 mcg over any 12 hours 0 12 24 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg • Tulobuterol was added as an example. • The statement on the urinary thresholds was improved. HORMONE AND METABOLIC MODULATORS • Clomifene is now stated by its INN. • In the absence of an INN, the IUPAC name of GW1516, 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl) thiazol-5-yl)methylthio)phenoxy) acetic acid as well as an alternative name (GW501516) were included. • SR9009, a Rev-Erb-α agonist, was added as an example of Activators of the AMP-activated protein kinase (AMPK). S3 Any 12 hour period: max. 800 mcg S4 SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2018 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) 2 DIURETICS AND MASKING AGENTS • In consideration of the information published in scientific articles since 2012 that particularly addresses the ability of glycerol to influence the athlete‘s plasma volume and parameters of the Athlete Biological Passport (ABP), the magnitude of glycerol-derived effects is regarded as minimal. Therefore, glycerol has been removed from the Prohibited List. Prohibited Methods CHEMICAL AND PHYSICAL MANIPULATION • M2.2: the permitted volume and timing of intravenous infusions were changed from infusions of no more than 50 mL per 6-hour period to no more than a total of 100 mL per 12-hour period in order to allow greater flexibility for the safe administration of non-prohibited therapeutic substances, for example, iron. • To reflect medical practice, “hospital admissions” has been changed to “hospital treatments” and “clinical investigations” has been clarified as “clinical diagnostic investigations”. GENE DOPING • The definition has been revised to include current and emerging gene manipulating technologies. Substances and Methods Prohibited In-Competition STIMULANTS • 1,3-Dimethylbutylamine was added as an example. This substance can be found in some dietary supplements. S5 M2 M3 S6 CANNABINOIDS • The category Cannabimimetics, e.g. “Spice, JWH-018, JWH-073, HU210” was changed to “synthetic cannabinoids, e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics”. The synthetic cannabinoids are one of the main classes of novel psychoactive substances that have constantly emerging new drugs and changing availability. The previous list of examples continues to be prohibited, but are currently used less commonly. “Other cannabimimetics” replaced these examples. • Cannabidiol is no longer prohibited. Synthetic cannabidiol is not a cannabimimetic; however, cannabidiol extracted from cannabis plants may also contain varying concentrations of THC, which remains a prohibited substance. GLUCOCORTICOIDS • Examples of commonly used glucocorticoids were added for greater clarity. S8 S9 3 Substances Prohibited in Particular Sports ALCOHOL • After careful consideration and extensive consultation, Alcohol was excluded from the Prohibited List. The intent of this change is not to compromise the integrity or safety of any sport where alcohol use is a concern, but rather to endorse a different means of enforcing bans on alcohol use in these sports. The four International Federations (IF) affected by this change have been alerted sufficiently in advance in order to amend their rules and to put in place protocols to test for alcohol use and appropriately sanction athletes who do not abide by the rules of their sport. Control of the process will allow IF more flexibility in applying rules or thresholds as they see fit. The National Anti-Doping Organizations are no longer obliged to conduct tests but may assist IF and National Federations where appropriate. BETA BLOCKERS • For logical consistency, the category known as P2. Beta Blockers was renamed P1. Beta Blockers. MONITORING PROGRAM The following were added to evaluate misuse in sport: • 2-ethylsulfanyl-1H-benzimidazole (bemitil) in- and out-of-competition • Hydrocodone in-competition. Mitragynine and telmisartan were removed from the Monitoring Program because the required information on prevalence was obtained. P1 P2

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2016 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.a, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regula- tory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 19-Norandrostenedione (estr-4-ene-3,17-dione); Bolandiol (estr-4-ene-3β,17β-diol ); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α- androst-2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); S0 S1 Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor- 17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol) 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone. Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeranol and zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietin-Receptor agonists: 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; Methoxy polyethylene glycol-epoetin beta (CERA). 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO. 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon. 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males. 4. Corticotrophins and their releasing factors, e.g corticorelin. S2 4 5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Except: • Inhaled salbutamol (maximum 1600 micrograms over 24 hours); • Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and • Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is pre- sumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a con- trolled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above. S3 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516; 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. S4 5 DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide). • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formo- terol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent. S5 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues; 2. The use of normal or genetically modified cells. M1 M2 M2 6 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-Methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylhexaneamine (dimethylpentylamine); Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; Selegiline; 7 Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2016 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS Prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS Prohibited: • Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC). • Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210. GLUCOCORTICOIDS All glucocorticoids are prohibited when adminis- tered by oral, intravenous, intramuscular or rectal routes. S7 S8 S9 8 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L. • Air Sports (FAI) • Automobile (FIA) • Archery (WA) • Powerboating (UIM) P1 BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea. *Also prohibited Out-of-Competition P2 Including, but not limited to: Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol. www.wada-ama.org

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2016 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.a, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regula- tory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 19-Norandrostenedione (estr-4-ene-3,17-dione); Bolandiol (estr-4-ene-3β,17β-diol ); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α- androst-2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); S0 S1 Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor- 17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol) 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone. Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeranol and zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietin-Receptor agonists: 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; Methoxy polyethylene glycol-epoetin beta (CERA). 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO. 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon. 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males. 4. Corticotrophins and their releasing factors, e.g corticorelin. S2 4 5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Except: • Inhaled salbutamol (maximum 1600 micrograms over 24 hours); • Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and • Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is pre- sumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a con- trolled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above. S3 HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516; 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. S4 5 DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide). • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formo- terol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent. S5 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues; 2. The use of normal or genetically modified cells. M1 M2 M2 6 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-Methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylhexaneamine (dimethylpentylamine); Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; Selegiline; 7 Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2016 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS Prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS Prohibited: • Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC). • Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210. GLUCOCORTICOIDS All glucocorticoids are prohibited when adminis- tered by oral, intravenous, intramuscular or rectal routes. S7 S8 S9 8 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L. • Air Sports (FAI) • Automobile (FIA) • Archery (WA) • Powerboating (UIM) P1 BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea. *Also prohibited Out-of-Competition P2 Including, but not limited to: Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol. www.wada-ama.org

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2017 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2017 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); Bolandiol (estr-4-ene-3β,17β-diol); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; S0 S1 Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: • Clenbuterol; • Selective androgen receptor modulators (SARMs, e.g. andarine and ostarine); • Tibolone; • Zeranol; • Zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietin-Receptor agonists: 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; GATA inhibitors, e.g. K-11706; Methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β (TGF-β) inhibitors, e.g. sotatercept, luspatercept; 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO. 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt, molidustat and roxadustat (FG-4592); and HIF activators, e.g. argon and xenon. S2 4 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males. 4. Corticotrophins and their releasing factors, e.g. corticorelin. 5. Growth Hormone (GH) and its releasing factors including: • Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; • Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; • GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin, and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Vilanterol. S3 Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant. S4 5 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516; 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol; • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues. 2. The use of normal or genetically modified cells. M1 M2 M3 6 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 7 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2017 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2017 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS Prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS Prohibited: • Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC). • Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes. S7 S8 S9 8 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L. • Air Sports (FAI) • Automobile (FIA) • Archery (WA) • Powerboating (UIM) P1 BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Levobunolol; Atenolol; Metipranolol; Betaxolol; Metoprolol; Bisoprolol; Nadolol; Bunolol; Oxprenolol; Carteolol; Pindolol; Carvedilol; Propranolol; Celiprolol; Sotalol; Esmolol; Timolol. P2 www.wada-ama.org

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2017 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2017 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); Bolandiol (estr-4-ene-3β,17β-diol); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; S0 S1 Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: • Clenbuterol; • Selective androgen receptor modulators (SARMs, e.g. andarine and ostarine); • Tibolone; • Zeranol; • Zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietin-Receptor agonists: 1.1 Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; GATA inhibitors, e.g. K-11706; Methoxy polyethylene glycol-epoetin beta (CERA); Transforming Growth Factor-β (TGF-β) inhibitors, e.g. sotatercept, luspatercept; 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290; Asialo EPO; Carbamylated EPO. 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt, molidustat and roxadustat (FG-4592); and HIF activators, e.g. argon and xenon. S2 4 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males. 4. Corticotrophins and their releasing factors, e.g. corticorelin. 5. Growth Hormone (GH) and its releasing factors including: • Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; • Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; • GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin, and pralmorelin (GHRP-2). Additional prohibited growth factors: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Vilanterol. S3 Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic dose (by inhalation) up to the maximum dose indicated above. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant. S4 5 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516; 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol; • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. S5 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of polymers of nucleic acids or nucleic acid analogues. 2. The use of normal or genetically modified cells. M1 M2 M3 6 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 7 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2017 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2017 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS Prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS Prohibited: • Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC). • Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular, or rectal routes. S7 S8 S9 8 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L. • Air Sports (FAI) • Automobile (FIA) • Archery (WA) • Powerboating (UIM) P1 BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Levobunolol; Atenolol; Metipranolol; Betaxolol; Metoprolol; Bisoprolol; Nadolol; Bunolol; Oxprenolol; Carteolol; Pindolol; Carvedilol; Propranolol; Celiprolol; Sotalol; Esmolol; Timolol. P2 www.wada-ama.org

THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2018 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2018 2 IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. ANABOLIC AGENTS Anabolic agents are prohibited. 1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including: 1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); Bolandiol (estr-4-ene-3β,17β-diol); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy- 17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst- 2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); Gestrinone; S0 S1 Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- 3-one); Metenolone; Methandriol; Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H- pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α- pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). 3 b. Endogenous** AAS when administered exogenously: 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α- androstan-3-one); Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone; and their metabolites and isomers, including but not limited to: 3β-Hydroxy-5α-androstan-17-one; 5α-Androst-2-ene-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β, 17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone. 2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine, LGD-4033, ostarine and RAD140), tibolone, zeranol and zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited: 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to: 1.1 Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). 1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. Argon; Cobalt; Molidustat; Roxadustat (FG-4592); Xenon. 1.3 GATA inhibitors, e.g. K-11706. 1.4 TGF-beta (TGF-β) inhibitors, e.g. Luspatercept; Sotatercept. S2 4 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). 2. Peptide Hormones and Hormone Modulators, 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin, in males; 2.2 Corticotrophins and their releasing factors, e.g. Corticorelin; 2.3 Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin, ipamorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and hexarelin. 3. Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin-β4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF). Additional growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. BETA-2 AGONISTS All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tulobuterol; Vilanterol. Except: • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. HORMONE AND METABOLIC MODULATORS The following hormone and metabolic modulators are prohibited: 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); S3 S4 5 Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene. 3. Other anti-estrogenic substances including, but not limited to: Clomifene; Cyclofenil; Fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. 5. Metabolic modulators: 5.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516); 5.2 Insulins and insulin-mimetics; 5.3 Meldonium; 5.4 Trimetazidine. DIURETICS AND MASKING AGENTS The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s). Including, but not limited to: • Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan. S5 Except: • Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. 6 PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. 2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases. 2. Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M1 M2 GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The use of polymers of nucleic acids or nucleic acid analogues. 2. The use of gene editing agents designed to alter genome sequences and/or the transcriptional or epigenetic regulation of gene expression. 3. The use of normal or genetically modified cells. M3 7 IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION: SUBSTANCES & METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES STIMULANTS All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Stimulants include: a: Non-Specified Stimulants: Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane. A stimulant not expressly listed in this section is a Specified Substance. S6 b: Specified Stimulants. Including, but not limited to: 1,3-Dimethylbutylamine; 4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; 8 Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). Except: • Clonidine; • Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2018 Monitoring Program*. * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2018 Monitoring Program, and are not considered Prohibited Substances. ** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter. NARCOTICS The following narcotics are prohibited: Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine. CANNABINOIDS The following cannabinoids are prohibited: • Natural cannabinoids, e.g. cannabis, hashish and marijuana, • Synthetic cannabinoids e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics. Except: • Cannabidiol. GLUCOCORTICOIDS All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Including but not limited to: Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. S7 S8 S9 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS BETA-BLOCKERS Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated. • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Shooting (ISSF, IPC)* • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting, and variable weight apnoea. *Also prohibited Out-of-Competition Including, but not limited to: Acebutolol; Labetalol; Alprenolol; Levobunolol; Atenolol; Metipranolol; Betaxolol; Metoprolol; Bisoprolol; Nadolol; Bunolol; Oxprenolol; Carteolol; Pindolol; Carvedilol; Propranolol; Celiprolol; Sotalol; Esmolol; Timolol. P1 www.wada-ama.org